Experimental and Clinical Endocrinology & Diabetes

Session 1: Obesity: the most extensive non-communicable disease of the 21st century

1

Philip, W.; James, T.:

What are the health risks? The medical consequences of obesity and its health risks

•      
• Volltext PDF (190 kb)

7

Seidell, J. C.:

Societal and personal costs of obesity

•      
• Volltext PDF (53 kb)

10

de Leiva, A.:

What are the benefits of moderate weight loss?

•      
• Volltext PDF (66 kb)

14

Williamson, D. F.:

Weight loss and mortality in persons with type-2 diabetes mellitus: a review of the epidemiological evidence

•      
• Volltext PDF (145 kb)

22

Lean, M. E. J.:

Obesity — what are the current treatment options?

•      
• Volltext PDF (154 kb)

Session 2: The place of sibutramine in clinical practice

27

Rössner, S.:

Obesity - as seen by the patient and his family

•      
• Volltext PDF (54 kb)

29

Astrup, A.; Lundsgaard, C.:

What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice

•      
• Volltext PDF (101 kb)

35

Van Gaal, L. F.; Wauters, M. A.; De Leeuw, I. H.:

Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment

•      
• Volltext PDF (144 kb)